Who are Dexmedetomidine-esketamine combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combined dexmedetomidine-esketamine, Nebulized lidocaine and dexmedetomidine, Dexmedetomidine and Fentanyl, Ketamine , Lidocaine , Dexmedetomidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dexmedetomidine-esketamine-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dexmedetomidine-esketamine combination — Competitive Intelligence Brief

Dexmedetomidine-esketamine combination (Dexmedetomidine-esketamine combination) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-analgesic combination. Area: Anesthesia / Sedation.

marketed Sedative-analgesic combination Alpha-2 adrenergic receptor; NMDA receptor Anesthesia / Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine-esketamine combination (Dexmedetomidine-esketamine combination) — Peking University First Hospital. This combination pairs dexmedetomidine (an alpha-2 adrenergic agonist) with esketamine (an NMDA receptor antagonist) to produce sedation and analgesia with dissociative properties.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dexmedetomidine-esketamine combination TARGET	Dexmedetomidine-esketamine combination	Peking University First Hospital	marketed	Sedative-analgesic combination	Alpha-2 adrenergic receptor; NMDA receptor
Combined dexmedetomidine-esketamine	Combined dexmedetomidine-esketamine	Peking University First Hospital	marketed	Sedative-analgesic combination	Alpha-2 adrenergic receptor; NMDA receptor
Nebulized lidocaine and dexmedetomidine	Nebulized lidocaine and dexmedetomidine	Ain Shams University	marketed	Local anesthetic and sedative-analgesic combination	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Dexmedetomidine and Fentanyl	Dexmedetomidine and Fentanyl	University of Jordan	phase 3	Sedative-analgesic combination (alpha-2 agonist + opioid)	Alpha-2 adrenergic receptor (dexmedetomidine); mu-opioid receptor (fentanyl)
Ketamine , Lidocaine , Dexmedetomidine	Ketamine , Lidocaine , Dexmedetomidine	University of Saskatchewan	phase 3	Anesthetic combination / Sedative-analgesic combination	NMDA receptor (ketamine), voltage-gated sodium channels (lidocaine), alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-analgesic combination class)

Peking University First Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine-esketamine combination — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-esketamine-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab